gemlapodect (NOE-105) / Noema Pharma 
Welcome,         Profile    Billing    Logout  
 1 Disease   3 Trials   3 Trials   14 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gemlapodect (NOE-105) / Noema Pharma
2021-004424-15: A study to evaluate different doses of a medicine called NOE-105 for the treatment of patients with Tourette Syndrome.

Not yet recruiting
2
18
Europe
NOE-105, Capsule
Noema Pharma Australia Pty Ltd, Noema Pharma Australia Pty Ltd
Tourette Syndrome, Facial and vocal tics, Diseases [C] - Nervous System Diseases [C10]
 
 
ACTRN12621000319875: An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult male patients with Tourette Syndrome (TS).

Recruiting
2
10
 
Noema Pharma Australia Pty Ltd, Noema Pharma Australia PTY LTD
Tourette syndrome
 
 
NCT05583955: A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

Completed
2
75
US, RoW
NOE-105, Escalating dose levels of NOE-105, Placebo, Placebo to match
Noema Pharma AG
Childhood-Onset Fluency Disorder
10/23
11/23
Allevia2, NCT06315751: Efficacy and Safety of Gemlapodect in Adults and Adolescents With Tourette Syndrome

Not yet recruiting
2
180
NA
Gemlapodect, NOE-105, Placebo
Noema Pharma AG
Tourette Syndrome
12/26
12/26
RG7203: RG7203: P1 for Schizophrenia

Available
1
0
RoW
RG7203
Roche
Schizophrenia
 
 

Download Options